When combined with izTRAIL sorafenib caused a more pronounced inhibition of tumor growth than sorafenib alone (Figure 5, curve 4) that may be due to inhibition of main pathways of cell survival such as Akt, MAPK. The gene discussed is AKT1; the disease is neoplasm.